![](/images/graphics-bg.png)
Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
المؤلفون المشاركون
Kuo, Fu-Chen
Wu, Meng-Chieh
Yu, Fang-Jung
Wu, I-Chen
Liu, Min-Li
Huang, Yao-Kang
Liu, Chung-Jung
Kuo, Chao-Hung
Wang, Yao-Kuang
Wu, Deng-Chyang
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-07-16
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori.
A total of 162 patients with Helicobacter pylori infection were randomly assigned to either the 7-day triple therapy group (RAK regimen: rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg bid; n=81) or the bismuth plus triple therapy group (n=81).
In the RBAK group, bismuth subcitrate 360 mg twice daily was added to the RAK regimen.
A follow-up endoscopy or urea breath test was performed at least 4 weeks after eradication to confirm the treatment efficacy.
Comparable compliance and Helicobacter pylori eradication rates were observed in both groups in either intention-to-treat [RAK 72.8% (59/81) versus RBAK 77.8% (63/81); p=0.47] or per protocol analysis [RAK 74.7% (59/79) versus RBAK 81.8% (63/77); p=0.26].
Adverse effects were commonly reported (50.6% for both groups) although most of these did not cause cessation of treatment.
The resistance rate was 27.2% for metronidazole and 12.3% for clarithromycin.
Adding bismuth to the standard 7-day triple therapy did not substantially increase the eradication rate.
Further study is needed clarifying whether extending the duration of RBAK regimen to 10–14 days can lead to a better result.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Wu, Meng-Chieh& Wang, Yao-Kuang& Liu, Chung-Jung& Yu, Fang-Jung& Kuo, Fu-Chen& Liu, Min-Li…[et al.]. 2017. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterology Research and Practice،Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1156460
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Wu, Meng-Chieh…[et al.]. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterology Research and Practice No. 2017 (2017), pp.1-6.
https://search.emarefa.net/detail/BIM-1156460
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Wu, Meng-Chieh& Wang, Yao-Kuang& Liu, Chung-Jung& Yu, Fang-Jung& Kuo, Fu-Chen& Liu, Min-Li…[et al.]. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterology Research and Practice. 2017. Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1156460
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1156460
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)